The Bing Center for Waldenström's Macroglobulinemia provides care and new therapies through clinical trials to patients with Waldenström's macroglobulinemia and related Immunoglobulin M (IgM) disorders.
About the Center
The Bing Center for Waldenström's Macroglobulinemia provides a comprehensive range of services for patients with Waldenström's macroglobulinemia, including:
The Treatment Team
The Bing Center for Waldenström's Macroglobulinemia encompasses a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for Waldenström's macroglobulinemia and, someday, a cure.
Waldenström's Macroglobulinemia Leadership
Steven P. Treon, MD, PhD, Director, Bing Center for Waldenström’s Macroglobulinemia
Irene Ghobrial, MD, Director, Michele & Stephen Kirsch Laboratory
Waldenström's Macroglobulinemia Physicians
Claudia Paba-Prada, MD
Waldenström's Macroglobulinemia Nursing Team
Stacey Chuma, RN
Sandra Kanan, ARNP
Janet Kunsman, NP
Clinical Research
Each patient's care combines the finest treatments currently available for Waldenström's macroglobulinemia with innovative new therapies based on research discovered through the collaboration of the center's laboratories and many other scientists from around the world.
The Bing Center for Waldenström's Macroglobulinemia offers patients access to a wide range of clinical research trials. The main goal of clinical research at the Bing Center for Waldenström's Macroglobulinemia is to swiftly and efficiently take discoveries made in the laboratory to the clinic where they can benefit the health and well-being of the patient.
This include studies aimed at improving the outcomes of patients undergoing biological therapies using agents in trials such as Rituxan and bortezomib that attempt to kill Waldenström's macroglobulinemia tumor cells directly. The center also has clinical research trials evaluating supportive therapies like statins and phosphodiesterase inhibitors to help understand the mechanics of the disease.
Contact Us
New Patients
Waldenström's Macroglobulinemia: 617-632-3823 or 617-632-5138, or use this online form to make an appointment.
Current Patients
Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.
Fax
617-632-3730
Mailing address
Hematologic Malignancies Division
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215